174 related articles for article (PubMed ID: 26608853)
1. [Anti-RANKL antibody for the treatment of bone and cartilage destruction in rheumatoid arthritis].
Nakayamada S; Tanaka Y
Clin Calcium; 2015 Dec; 25(12):1787-93. PubMed ID: 26608853
[TBL] [Abstract][Full Text] [Related]
2. [Mechanism of bone and cartilage damage in rheumatoid arthritis].
Komatsu N; Takayanagi H
Clin Calcium; 2015 Dec; 25(12):1749-55. PubMed ID: 26608848
[TBL] [Abstract][Full Text] [Related]
3. [Anti-RANKL antibody for the treatment of rheumatoid arthritis].
Tanaka Y
Clin Calcium; 2011 Aug; 21(8):1223-9. PubMed ID: 21814029
[TBL] [Abstract][Full Text] [Related]
4. [Mechanism of bone destruction in rheumatoid arthritis and perspectives of the treatment].
Koyama T; Tanaka S
Clin Calcium; 2016 May; 26(5):735-41. PubMed ID: 27117620
[TBL] [Abstract][Full Text] [Related]
5. [Cytokines in bone diseases. Anti-cytokine therapies for bone and joint diseases].
Tanaka Y
Clin Calcium; 2010 Oct; 20(10):1545-52. PubMed ID: 20890038
[TBL] [Abstract][Full Text] [Related]
6. [Biomarker of bone and cartilage destruction in rheumatoid arthritis].
Tanimura S; Kato M; Atsumi T
Clin Calcium; 2015 Dec; 25(12):1769-75. PubMed ID: 26608851
[TBL] [Abstract][Full Text] [Related]
7. [Expectation for alleviation of joint destruction in rheumatoid arthritis by new molecular targeting pharmaceutics including anti-rankle antibody].
Nakamura T
Clin Calcium; 2009 Mar; 19(3):381-6. PubMed ID: 19252248
[TBL] [Abstract][Full Text] [Related]
8. [Secondary osteoporosis UPDATE. Rheumatoid arthritis and bone damage: trends in treatment].
Tanaka Y
Clin Calcium; 2010 May; 20(5):735-42. PubMed ID: 20445285
[TBL] [Abstract][Full Text] [Related]
9. [Diagnosis and treatment of rheumatoid arthritis:toward the best practice. Anti-bone resorbing treatment for rheumatoid arthritis.].
Tanaka Y
Clin Calcium; 2018; 28(5):630-636. PubMed ID: 29731457
[TBL] [Abstract][Full Text] [Related]
10. [The regulation of CTLA4-Ig in bone and cartilage destruction of rheumatoid arthritis].
Iwamoto N; Kawakami A
Clin Calcium; 2015 Dec; 25(12):1817-23. PubMed ID: 26608857
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of anti-cytokines and anti-RANKL antibody for treatment of RA and osteoporosis].
Okada Y; Nawata M; Tanaka Y
Clin Calcium; 2007 Nov; 17(11):1762-8. PubMed ID: 17982198
[TBL] [Abstract][Full Text] [Related]
12. IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis.
Mori T; Miyamoto T; Yoshida H; Asakawa M; Kawasumi M; Kobayashi T; Morioka H; Chiba K; Toyama Y; Yoshimura A
Int Immunol; 2011 Nov; 23(11):701-12. PubMed ID: 21937456
[TBL] [Abstract][Full Text] [Related]
13. Review: Immune cells and mediators of inflammatory arthritis.
Schett G
Autoimmunity; 2008 Apr; 41(3):224-9. PubMed ID: 18365836
[TBL] [Abstract][Full Text] [Related]
14. RANKL: A therapeutic target for bone destruction in rheumatoid arthritis.
Tanaka S; Tanaka Y; Ishiguro N; Yamanaka H; Takeuchi T
Mod Rheumatol; 2018 Jan; 28(1):9-16. PubMed ID: 28880683
[TBL] [Abstract][Full Text] [Related]
15. Anti-receptor activator of nuclear factor κB ligand antibody treatment increases osteoclastogenesis-promoting IL-8 in patients with rheumatoid arthritis.
Morita T; Shima Y; Fujimoto K; Tsuboi H; Saeki Y; Narazaki M; Ogata A; Kumanogoh A
Int Immunol; 2019 Apr; 31(5):277-285. PubMed ID: 30753461
[TBL] [Abstract][Full Text] [Related]
16. Enhanced immunoprotective effects by anti-IL-17 antibody translates to improved skeletal parameters under estrogen deficiency compared with anti-RANKL and anti-TNF-α antibodies.
Tyagi AM; Mansoori MN; Srivastava K; Khan MP; Kureel J; Dixit M; Shukla P; Trivedi R; Chattopadhyay N; Singh D
J Bone Miner Res; 2014 Sep; 29(9):1981-92. PubMed ID: 24677326
[TBL] [Abstract][Full Text] [Related]
17. [The "treat-to-target" strategies for rheumatoid arthritis and managing for bone cartilage destructions].
Kondo Y; Kaneko Y; Takeuchi T
Clin Calcium; 2015 Dec; 25(12):1757-62. PubMed ID: 26608849
[TBL] [Abstract][Full Text] [Related]
18. Serum RANKL levels associate with anti- citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexate.
Hensvold AH; Joshua V; Li W; Larkin M; Qureshi F; Israelsson L; Padyukov L; Lundberg K; Defranoux N; Saevarsdottir S; Catrina AI
Arthritis Res Ther; 2015 Sep; 17(1):239. PubMed ID: 26337028
[TBL] [Abstract][Full Text] [Related]
19. An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases.
Maldonado-Gonzales E; Pietschmann P
Wien Med Wochenschr; 2010 Sep; 160(17-18):458-63. PubMed ID: 20714812
[TBL] [Abstract][Full Text] [Related]
20. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
